Docosahexaenoic Acid in the Treatment of Autism

Completed · Not applicable · Has a placebo group

Conditions studied: Autism

In brief

The purpose of this study is to test the hypothesis that dietary supplementation with the omega-3 fatty acid docosahexaenoic acid (DHA) improves the behavior of children with autism.

Key facts

Study ID

NCT00577447

Run by

Mayo Clinic

People needed

48

Starts

2005-10-01

Expected to finish

2007-11-01

Last updated by the study team

2015-04-28

Who can join

Age: 3 and older, up to 10. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Meet DSM-IV criteria for autistic disorder
• Age 3 to 10 years

You may not qualify if…

• Use of a dietary supplement containing DHA within 90 days of study inclusion
• Medical history of a disorder of lipid metabolism

Where it is running

• Mayo Clinic — Rochester, Minnesota, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.